Relating to health benefit plan coverage for chimeric antigen receptor T-cell therapy.

HB 3057 requires most health insurance plans in Texas to cover chimeric antigen receptor T-cell (CAR-T) therapy, a specialized cancer treatment. It applies to individual, group, and employer-sponsored health benefit plans (including HMOs, health maintenance organizations, and plans under Chapter 1501), but excludes Medicaid and child health programs. The law mandates that these plans provide coverage for CAR-T therapy without prior authorization or excessive cost-sharing. This policy change directly affects patients with eligible cancers and insurers offering covered health plans in Texas, ensuring access to this advanced treatment.